Barcode Five Rights System



Use Barcode to prevent medication errors



ADERS ® is a barcode point of care, (BPOC), solution

Request Info











Practical Compliance Solutions, Corp. helps care facilities reduce risk at the patient's bedside. Our five rights barcode solution is the easiest to implement. Our barcode point of care system can help prevent medication errors in hospitals, long term care facilities, and assisted living communities.

ADERS ® is our barcode solution for the healthcare industry. It helps eliminate medication errors by allowing caregivers to scan NDC barcodes at the patient's bedside, verifying right patient, right drug, right time, right dose, and right route of administration. For more information click the products menu or send us a web request from our Contact menu. Ask for a DEMO CD. It is the full product that is licensed for an evaluation period.

We are offering a 30 day no-obligation free trial of the ADERS ® software. Care facilities can easily determine if ADERS ® is right for them by using the software as a pilot for a single unit or ward. Click here to download a Microsoft Project plan showing how you can implement a five rights point of care barcode pilot in less than a week. If you Don't own MS Project 2003, then here is a PDF copy just to see.... Download Adobe PDF Data Sheet

View a PowerPoint Presentation of ADERS ®.





Current Patient Safety and Drug Safety Updates from the FDA


FDA Press Releases RSS Feed

FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
Mon, 18 Mar 2024 13:52:03 EDT

  Lenmeldy is the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

FDA Roundup: March 15, 2024
Fri, 15 Mar 2024 16:47:37 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease
Thu, 14 Mar 2024 15:58:34 EDT

  The FDA approved the first medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring, to be used along with diet and exercise.

FDA Roundup: March 12, 2024
Tue, 12 Mar 2024 15:54:41 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Seeks $7.2 Billion to Enhance Food Safety and Nutrition, Advance Medical Product Safety, and Strengthen Public Health
Mon, 11 Mar 2024 15:01:45 EDT

  FDA seeks $7.2 Billion to enhance food safety and nutrition, advance medical product safety, help support supply chain resiliency, strengthen the agency’s public-health and mission-support capacity, and modernize the FDA’s infrastructure, buildings, and facilities

FDA Roundup: March 8, 2024
Fri, 08 Mar 2024 15:26:03 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Fri, 08 Mar 2024 13:59:11 EST

  The FDA approved a new use for a drug to reduce the risk of cardiovascular disease, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.

FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US
Wed, 06 Mar 2024 15:28:52 EST

  FDA takes additional steps to address concerns about elevated lead levels in cinnamon following the recent incident associated with certain cinnamon apple sauce pouches that resulted in lead poisoning in young children.

FDA Roundup: March 5, 2024
Tue, 05 Mar 2024 17:37:45 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Clears First Over-the-Counter Continuous Glucose Monitor
Tue, 05 Mar 2024 16:21:57 EST

  Today, the U.S. Food and Drug Administration cleared for marketing the first over-the-counter continuous glucose monitor.

FDA Roundup: March 1, 2024
Fri, 01 Mar 2024 15:58:34 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA, Industry Actions End Sales of PFAS Used in US Food Packaging
Wed, 28 Feb 2024 13:43:13 EST

  FDA announced that grease-proofing substances containing PFAS are no longer being sold by manufacturers for food contact use in the U.S. market. The completion of the voluntary market phase-out of these substances used on food packaging paper and paperboard, eliminates the primary source of dietary

FDA Roundup: February 27, 2024
Tue, 27 Feb 2024 15:58:26 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: February 23, 2024
Fri, 23 Feb 2024 16:07:11 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Roundup: February 20, 2024
Tue, 20 Feb 2024 17:10:20 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma
Fri, 16 Feb 2024 15:27:05 EST

  The FDA approved Amtagvi, the first cellular therapy for the treatment of adults with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

FDA Roundup: February 16, 2024
Fri, 16 Feb 2024 15:22:35 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure
Fri, 16 Feb 2024 11:57:35 EST

  The FDA approved a new medication for the reduction of allergic reactions that may occur with accidental exposure to one or more foods. Patients who take this medication must continue to avoid foods they are allergic to.

FDA Approves First Medication to Treat Severe Frostbite
Wed, 14 Feb 2024 09:15:47 EST

  The FDA approved an injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

FDA Roundup: February 13, 2024
Tue, 13 Feb 2024 12:38:28 EST

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Food and Drugs Administration--Recalls/Safety Alerts

Wenders LLC Recalls Trader Joes Nuts – 50% Less Sodium Roasted & Salted Whole Cashews Because of Possible Health Risk
Sun, 17 Mar 2024 00:00:00 EDT

  Wenders LLC of Dublin, CA is recalling specific production lots of Trader Joes Nuts – 50% Less Sodium Roasted & Salted Whole Cashews – (SKU Number – 37884) Lot# T12139, T12140, T12141, and T12142 because they have the potential to be contaminated with Salmonella, an organism which can cause serious

Kick Ash Products Issues Allergy Alert on Undeclared Almonds in Product
Thu, 14 Mar 2024 00:00:00 EDT

  Kick Ash Products of Ellison Bay, WI is recalling Door County Love Dark Chocolate Cherry Granola with Lot #061241, because it may contain undeclared ALMONDS. People who have an allergy or severe sensitivity to almonds run the risk of serious or life-threatening allergic reaction if they consume the

Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Tue, 12 Mar 2024 14:53:00 EDT

  Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulate

John B. Sanfilippo & Son, Inc Issues Allergy Alert on Undeclared Coconut and Milk in Great Value Honey Roasted Cashews 8.25 Oz
Tue, 12 Mar 2024 00:00:00 EDT

  John B. Sanfilippo & Son, Inc (JBSS) announced today it is voluntarily recalling a limited amount of 8.25 oz Great Value Honey Roasted Cashews, because it may contain undeclared coconut and milk. People who have an allergy or severe sensitivity to coconut or milk run the risk of serious or life-thre

Wesco, Inc. Issues Voluntary Recall and Allergy Alert on Undeclared Peanut in Wesco Mint No Bake Cookie Bites
Fri, 08 Mar 2024 00:00:00 EST

  Wesco, Inc. of Muskegon, MI is recalling 750 units of Wesco Mint No Bake Cookie Bites, because it may contain undeclared peanut. People who have an allergy or severe sensitivity to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products. The affected Wesc

Stonewall Kitchen Issues Allergy Alert for Wheat in Limited Quantity of Gluten Free Cinnamon Sugar Doughnut Mix
Thu, 07 Mar 2024 00:00:00 EST

  Stonewall Kitchen of York, Maine is voluntarily recalling a limited amount of their Gluten Free Cinnamon Sugar Doughnut Mix because it may contain an undeclared allergen, wheat. People who have an allergy or severe sensitivity to wheat (which contains gluten) may risk serious allergic reaction if t

El Chilar Rodriguez LLC. Issues Voluntary Recall of El Chilar Ground Cinnamon “Canela Molida” Due to Elevated Lead Levels
Wed, 06 Mar 2024 18:00:00 EST

  El Chilar Rodriguez LLC of Apopka, FL is recalling 127 cases (12 bags/case) of El Chilar Ground Cinnamon “Canela Molida” (1.25 oz bag), because it may contain traces of lead.

Colonna Brothers, Inc. Issues a Voluntary Recall for “1.5oz Marcum Ground Cinnamon & 2.25oz Supreme Tradition Ground Cinnamon” Because of Possible Health Risk Due to Elevated Lead Levels
Wed, 06 Mar 2024 17:10:00 EST

  Colonna Brothers of North Bergen, NJ is recalling its 1.5oz Marcum Ground Cinnamon & 2.25oz Supreme Tradition Ground Cinnamon because of a possible health risk due to elevated lead levels. Short term exposures to very low levels of lead may not elicit any symptoms. It is possible that increased bloo

Expanded Press Release – Kalo Foods, LLC Recalls Single Slice Carrot Cake and Chocolate Cake Due to Undeclared Soy Allergen
Wed, 06 Mar 2024 11:00:00 EST

  KALO Foods, LLC is recalling Single Slice Carrot Cake UPC 8 53407 00418 4 and Single Slice Chocolate Cake UPC 8 53407 00418 4 due to a undeclared soy.

La Fiesta Food Products Recalls Cinnamon Ground Because of Possible Health Risk
Wed, 06 Mar 2024 00:00:00 EST

  La Fiesta Food Products, La Mirada California is recalling Cinnamon Ground .87oz because it has the potential to be contaminated with lead. Short term exposures to very low levels of lead may not elicit any symptoms. It is possible that increased blood lead levels may be the only apparent sign of le

Raja Foods Skokie, IL Is Recalling “Swad Brand Cinnamon Powder 3.5OZ Retail Packs” for Possible Lead Contamination
Wed, 06 Mar 2024 00:00:00 EST

  Raja Foods LLC of Skokie, Il is recalling its 3.5 ounce package of "SWAD CINNAMON POWDER" because it has the potential to be contaminated with lead.

Kalo Foods, LLC Recalls Single Slice Carrot Cake Due to Undeclared Soy Allergen
Tue, 05 Mar 2024 17:25:00 EST

  KALO Foods, LLC is recalling Single Slice Carrot Cake UPC 8 53407 00418 4 due to a undeclared soy. Although the package is labeled Carrot Cake, the ingredient panel and UPC Code is for their Chocolate Cake. The Carrot Cake contains soy which is not listed in the ingredient statement. People who hav

Sleepnet Corporation Issues Worldwide Recall of CPAP and BIPAP Masks with Magnets Due to Potential Interference with Certain Medical Implants
Fri, 01 Mar 2024 00:00:00 EST

  Hampton, NH – On March 1, 2024, Sleepnet Corporation initiated a worldwide recall for all CPAP and BIPAP masks with magnets due to potential interference with certain medical devices. When a magnet comes into close proximity to certain medical implants or metallic implants, it could interfere with t

Aji Mori Sauce Corp. DBA Sushi Koo Issues Voluntary Recall of Chillimami Sauce
Thu, 29 Feb 2024 00:00:00 EST

  Aji Mori Sauce Corp. DBA Sushi Koo of Los Angeles, CA, is voluntarily recalling its CHILLIMAMI SAUCE because product was manufactured and distributed without the California Department of Public Health (CDPH) Cannery Program oversight, making them just susceptible to contamination with Clostridium bo

Megadyne Reiterates Intended Use Population Change for Megadyne Mega Soft Universal and Universal Plus Patient Return Electrodes
Thu, 29 Feb 2024 00:00:00 EST

  Megadyne issued a Class 1 Medical Device Correction to hospitals to limit the use of MEGA SOFT Universal and Universal Plus Reusable Patient Return Electrodes to patients aged 12 years or older after receiving reports of adult and pediatric patient burns following surgical procedures in which MEGA S

Electric City Sweets Issues Allergy Alert On Undeclared Milk in Electric City Sweet 1.75oz Red Velvet Milk Chocolate Bars
Wed, 28 Feb 2024 10:51:00 EST

  Electric City Sweets of Scranton, PA is recalling 1,644 Red Velvet Milk Chocolate Bars, due to undeclared milk in the ingredient statement and allergen statement. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume th

Roland Foods, LLC Recalls Roland® Tahini (100% Ground Sesame Seeds) 16 Oz. Because of Possible Health Risk
Tue, 27 Feb 2024 00:00:00 EST

  Roland Foods, LLC (“Roland Foods”) of New York, New York is recalling a specific production code of Roland® Tahini (100% Ground Sesame Seeds) 16 oz. because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children,

G.A. Mart Issues Voluntary Nationwide Recall of H&NATURAL TejoRoot and H&NATURAL Brazil Seed Dietary Supplements Due to the Presence of Yellow Oleander (Thevetia peruviana), a Poisonous Plant Native to Mexico and Central America
Fri, 23 Feb 2024 18:35:00 EST

  February 22, 2024 – San Luis, AZ, G.A. Mart dba H&Natural, is voluntarily recalling 2 lots of H&NATURAL TejoRoot, 10g pills and 2 lots of H&NATURAL Brazil Seed, .167g Seeds to the consumer level. The products have been found via random FDA testing to contain yellow oleander, a poisonous plant native

Backstage Center is Issuing a Recall of Approximately 280 Bottles of Alipotec Raiz de Tejocote, Dietary Supplements, that are Labeled with the "Alipotec King" Sticker
Fri, 23 Feb 2024 00:00:00 EST

  Backstage Center is issuing a recall of approximately 280 Bottles of Alipotec Raiz de Tejocote, dietary supplements, that are labeled with the "Alipotec King" sticker. This recall is being initiated because FDA analysis found that the product contains toxic yellow oleander. The recalled product, whi

LQNN, Inc. Issues Allergy Alert on Undeclared Egg in Banh Ba Xa and Banh Pia Products
Fri, 23 Feb 2024 00:00:00 EST

  LQNN Inc., of Garden Grove, California, is voluntarily recalling Banh Ba Xa and varieties of Banh Pia because they may contain undeclared egg. People who have an allergy or severe sensitivity to eggs run the risk of serious or life-threatening allergic reaction if they consume these products. The af

What's New: Drugs RSS Feed

Novel Drug Approvals for 2018
Mon, 18 Mar 2024 18:24:32 EDT

  Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process.

Generic Drug Facilities, Sites and Organization Lists
Mon, 18 Mar 2024 15:58:54 EDT

  Generic Drug Facilities, Sites and Organization Lists

What's New Related to Drugs
Mon, 18 Mar 2024 15:38:59 EDT

  Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

Artificial Intelligence and Machine Learning (AI/ML) for Drug Development
Mon, 18 Mar 2024 15:02:32 EDT

  Computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making prediction

Novel Drug Approvals for 2019
Mon, 18 Mar 2024 14:52:09 EDT

  Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process.

Novel Drug Approvals for 2022
Mon, 18 Mar 2024 14:43:52 EDT

  Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products
Mon, 18 Mar 2024 14:41:35 EDT

  Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process.

Multimedia Education Materials | Biosimilars
Mon, 18 Mar 2024 14:29:03 EDT

  FDA offers a variety of materials in multiple formats to help promote understanding of biosimilars and interchangeable products.

Controlled Correspondence Related to Generic Drug Development
Mon, 18 Mar 2024 11:55:46 EDT

  Controlled Correspondence Related to Generic Drug Development

Q&A with FDA Podcast
Mon, 18 Mar 2024 11:48:59 EDT

  “Q&A with FDA” is a monthly podcast series that provides engaging conversation and discussion about the latest regulatory topics. In this podcast series, FDA’s Division of Drug Information will answer some of the most commonly asked questions received by FDA. Perhaps you have had the same questions

From Our Perspective: The Orange Book at 40: A Valued FDA Resource Continually Enhanced by User Input
Mon, 18 Mar 2024 11:46:56 EDT

  From Our Perspective: The Orange Book at 40: A Valued FDA Resource Continually Enhanced by User Input

From Our Perspective: FDA Actions to Continue to Ensure the Safety of the Nation’s Drug Supply
Mon, 18 Mar 2024 11:44:23 EDT

  From Our Perspective: FDA Actions to Continue to Ensure the Safety of the Nation’s Drug Supply

CDER Collaborates with Global Regulators on Pharmaceutical Quality Assessments and Inspections
Mon, 18 Mar 2024 11:42:13 EDT

  Regulators collaboration enable industry to reliably supply critical medicines for patients

From Our Perspective
Mon, 18 Mar 2024 11:38:29 EDT

  Insights from CDER leadership and experts on public health actions

User Fee Lists
Mon, 18 Mar 2024 11:31:32 EDT

  Fiscal Year (FY) 2017 GDUFA facility fees are due on October 3, 2016.

More CDER Conversations
Mon, 18 Mar 2024 11:26:18 EDT

  Conversation with FDA scientists regarding current events.

CDER Communications Testing: Optimizing Drug Information Through Target Audience Feedback
Mon, 18 Mar 2024 11:26:17 EDT

  Social and behavioral scientists in CDER’s Office of Communications (OCOMM) collect feedback from target audience members on a variety of drug-related messages and information to help make sure the groups understand the communications shared with them.

Improving Medication Adherence and Patient Experience by Researching Patient Perceptions of Generic Drugs
Mon, 18 Mar 2024 11:26:16 EDT

  OGD conducts and funds research to better understand how we can best educate patients and health care providers about generic drugs

CDER’s Drug Quality Sampling and Testing Program
Mon, 18 Mar 2024 11:26:13 EDT

  CDER’s Office of Pharmaceutical Quality oversees the quality surveillance program using a targeted, risk-based approach to ensure the availability of safe, effective, quality drugs for the American public.

An Update on Sunscreen Requirements: The Deemed Final Order and the Proposed Order
Mon, 18 Mar 2024 11:26:11 EDT

  FDA is posting the deemed final order for over-the-counter (OTC) sunscreens and is issuing a proposed order for sunscreens. This explains today’s activities and what the orders mean for consumers, health care providers, industry, and other stakeholders.


Whats New Vaccines Blood Biologics RSS Feed

Licensed Biological Products with Supporting Documents
Mon, 18 Mar 2024 16:25:50 EDT

  Licensed biological products with supporting documents is arranged alphabetically by the proper name of the product(s). Information is provided for original product approvals, new indications, and the current package insert.

What’s New for Biologics
Mon, 18 Mar 2024 16:23:21 EDT

  Latest news from the Center for Biologics Evaluation and Research

Biologics PREA Reviews and Labeling Changes
Mon, 18 Mar 2024 16:22:16 EDT

  PREA Labeling Changes, Medical, Statistical, and Clinical Pharmacology Reviews of Pediatric Studies Conducted under Section 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA). These assessments are for CBER regulated drugs approved under

Artificial Intelligence and Machine Learning (AI/ML) for Drug Development
Mon, 18 Mar 2024 15:02:32 EDT

  Computer science, statistics, and engineering that uses algorithms or models to perform tasks and exhibit behaviors such as learning, making decisions, and making prediction

ABRYSVO
Mon, 18 Mar 2024 14:24:25 EDT

  ABRYSVO is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.


FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy
Mon, 18 Mar 2024 13:52:03 EDT

  Lenmeldy is the first FDA-approved gene therapy indicated for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD).

Enforcement Actions (CBER)
Mon, 18 Mar 2024 12:37:43 EDT

  The Center for Biologics Evaluation and Research (CBER) may issue several types of regulatory action letters. These letters are ordinarily issued to biological product manufacturers in the effort to stop practices found to be in violation of the regulations and to promote corrective action.

Approved Cellular and Gene Therapy Products
Mon, 18 Mar 2024 12:12:01 EDT

  Listing of licensed and approved products from the Office of Tissues and Advanced Therapies (OTAT).

Jobs at the Center for Biologics Evaluation and Research (CBER)
Mon, 18 Mar 2024 08:21:34 EDT

  CBER has unique opportunities for individuals with backgrounds in science or administration to fill positions involved in the regulation and research of blood, vaccines and therapeutics.

Remarks by Commissioner Robert M. Califf to the 2023 Global Summit on Regulatory Science - 09/26/2023
Fri, 15 Mar 2024 17:38:13 EDT

  Remarks by Robert M. Califf, M.D.
Commissioner of Food and Drugs
2023 Global Summit on Regulatory Science
Sept. 26, 2023


FDA Roundup: March 15, 2024
Fri, 15 Mar 2024 16:48:33 EDT

  The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Wilate
Fri, 15 Mar 2024 15:50:57 EDT

  In adults and adolescents with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and for on-demand treatment and control of bleeding episodes.

eSubmitter Application History
Fri, 15 Mar 2024 15:03:47 EDT

  History of all updates to the application software in reverse chronological order by version number

Recently Issued Guidance Documents
Fri, 15 Mar 2024 14:24:39 EDT

  This page lists Recently Issued CBER and Cross-Center Guidance Documents.

Devices Guidances
Fri, 15 Mar 2024 14:23:21 EDT

  This page lists Medical Device Guidance documents.

FDA Voices
Fri, 15 Mar 2024 13:55:06 EDT

  Insights from FDA leadership and experts into the agency's work on policy, consumer safety & enforcement, medical products, food, & tobacco.

CDER Scientific Review Documents Supporting Emergency Use Authorizations for Drug and Biological Therapeutic Products | COVID-19
Fri, 15 Mar 2024 11:35:37 EDT

  CDER Scientific Reviews Supporting EUA for Therapeutic Products

Harnessing the Potential of Artificial Intelligence
Fri, 15 Mar 2024 08:46:50 EDT

  At the FDA, we’ve been working for years to anticipate and prepare for the challenges of Artificial Intelligence (AI), and also to harness its potential.

GARDASIL 9
Fri, 15 Mar 2024 06:55:58 EDT

  Product approval information for Human Papillomavirus 9-valent Vaccine, Recombinant also known as Gardasil 9.

BIMO/Team Biologics/Internet Surveillance/Other
Thu, 14 Mar 2024 15:26:45 EDT

  This is the main page for the CBER BIMO/Team Biologics/Internet Surveillance/Other.





See how to prevent medication errors with bar codes using ADERS. Get your free pilot started today.





 
 

Contact Us


Corporate Headquarters


Practical Compliance Solutions
One Orient Way
Suite F156
Rutherford, NJ 07070
  201-728-8809


40.827731 N 74.101029 W

Connect With Us

   
 
 
© 2002 - 2024 - Copyright Practical Compliance Solutions - All rights reserved